To include your compound in the COVID-19 Resource Center, submit it here.

Ophthalmic deals

Ophthalmic deals

Date Companies Value [upfront; milestones/royalties] Description
Sep 08 Acucela/Otsuka (Tokyo:4768) [$5M; up to $258M] Partner to develop a pair of compounds for ophthalmic indications: Acucela's ACU-4429 for dry age-related macular degeneration (AMD) and potentially other indications such as diabetic retinopathy; and Otsuka's rebamipide
Aug 08 Eyetech/OSI (NASDAQ:OSIP) [$0; undisclosed] OSI employees purchase the assets of the company's Eyetech business to form newco Eyetech Inc. which includes OSI's remaining ophthalmic assets, including U.S. rights to Macugen pegaptanib to treat wet AMD
Aug 08 Asterand (LSE:ATD)/Allergan (NYSE:AGN) [$6.3M; up to $56M] Allergan obtains exclusive worldwide rights to undisclosed preclinical small molecule prostaglandin receptor agonists for ophthalmic indications

Read the full 1224 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers